Cargando…

Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study

OBJECTIVE: To evaluate the long-term safety and effectiveness of tadalafil in Japanese men with lower urinary tract symptoms secondary to benign prostatic hyperplasia in real-world clinical practice; and to investigate the safety profile in patients aged ≥75 years. PATIENTS AND METHODS: This was a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Hiroyoshi, Tsujimoto, Naoto, Koyanagi, Momoha, Katoh, Megumi C, Tajima, Koyuki, Komori, Mika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210025/ https://www.ncbi.nlm.nih.gov/pubmed/32440247 http://dx.doi.org/10.2147/POR.S237821

Ejemplares similares

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
por: Angalakuditi, Mallik, et al.
Publicado: (2010)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
por: Pogula, Vedamurthy Reddy, et al.
Publicado: (2019)

Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
por: Ahmad, Malik Suhail, et al.
Publicado: (2022)

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus
por: Elkelany, Osama O, et al.
Publicado: (2015)

The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
por: Lee, Sung Won, et al.
Publicado: (2014)

Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study
por: Won, Ji Eon, et al.
Publicado: (2018)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
por: Alsaikhan, Bader, et al.
Publicado: (2014)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials
por: Guo, Boda, et al.
Publicado: (2020)

Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis
por: Cui, Jianwei, et al.
Publicado: (2021)

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia
por: Tanaka, Tomoaki, et al.
Publicado: (2018)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis
por: Fusco, Ferdinando, et al.
Publicado: (2015)

Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation
por: Alhakamy, Nabil A., et al.
Publicado: (2019)

Japanese giant benign prostatic hyperplasia: Sibling cases
por: Ohyama, Takehiro, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
por: Zhou, Rui, et al.
Publicado: (2023)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
por: Pattanaik, Smita, et al.
Publicado: (2019)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study
por: Takahashi, Satoru, et al.
Publicado: (2020)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Publicado: (2019)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma
por: Abdel Moneim, Mona M.
Publicado: (2022)

Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management
por: Muruganandham, K., et al.
Publicado: (2007)

Large bowel obstruction caused by urinary retention from benign prostate hyperplasia
por: Fujisaki, Tomohiro, et al.
Publicado: (2018)

Lower urinary tract symptoms and benign prostatic hyperplasia: From research to bedside
por: Goel, Apul
Publicado: (2019)

Benign Prostatic Hyperplasia
Publicado: (2015)

Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
por: Choi, Ho Chul, et al.
Publicado: (2015)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
por: Ahn, Sun Tae, et al.
Publicado: (2020)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

Lifestyle habits to prevent the development of benign prostatic hyperplasia: Analysis of Japanese nationwide datasets
por: Nagakura, Yukinori, et al.
Publicado: (2022)

The Urinary Tract Microbiome in Male Genitourinary Diseases: Focusing on Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms
por: Kim, Myung Soo, et al.
Publicado: (2021)

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
por: Parsons, J. Kellogg
Publicado: (2010)

Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
por: Vasanwala, Farhad Fakhrudin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1kfrjob4b0o3gr2pr3mh1tap63